Solitary fibrous tumor of the renal pelvis: A case report

Liu M et al. Renal pelvis solitary fibrous tumor

Min Liu, Chao Zheng, Jin Wang, Jixue Wang, Liang He

Abstract

BACKGROUND
Solitary fibrous tumor (SFT) is rare mesenchymal neoplasm. SFT derived from the renal pelvis is an exceedingly rare entity. In this study, we report a case of renal pelvis SFT and review the relevant literature on this rare tumor.

CASE SUMMARY
A 76-year-old man was hospitalized due to right lumbar and abdominal pain. Abdominal computed tomography (CT) showed hypervascular space-occupying renal lesion, sized 2.3 cm×1.8 cm. Based on the CT findings, the patient was diagnosed with right renal pelvis tumor and underwent nephrectomy. Postoperative immunohistochemical results confirmed the diagnosis. As of three-year follow-up, there are no signs of recurrence and the patient has recovered well.

CONCLUSION
We report a rare case of SFT derived from the renal pelvis and discuss the imaging and histopathological features that distinguish renal pelvis SFT from other renal pelvis tumors.
**Key Words:** Renal pelvis; Solitary fibrous tumor; Surgery; Computed tomography; Case report


**Core Tip:** Renal pelvis; Solitary fibrous tumor; Surgery; Computed tomography; Case report

**INTRODUCTION**
Solitary fibrous tumors (SFTs) were reported for the first time by Wagner et al[1] in 1870. As hemangiopericytomas, SFTs are usually benign and arise from mesenchymal spindle cells, typically of the pleura. Extra-pleural SFTs are relatively rare[2]. Although several cases of SFT have been reported, the cause of SFT remains unknown[3]. Most of the SFTs are benign lesions with slow progress, but some have malignant potential[4]. Renal pelvis SFT is an extremely rare entity, with only 11 cases reported in the published literature[5]. Renal pelvis SFT is liable to be misdiagnosed as renal cell carcinoma (RCC), upper-tract urothelial cancers (UTUCs), and renal angiomyolipoma (RAML). The diagnosis and treatment of renal pelvis SFT is challenging. In this work, we report a rare case of renal pelvis SFT. In addition, we review the relevant literature to facilitate accurate diagnosis and treatment of renal pelvis SFT.

**CASE PRESENTATION**

*Chief complaints*
A 76-year-old man (height: 167 cm; weight: 70 kg) presented in our hospital for persistent right lumbar and abdominal pain.

*History of present illness*
The right lumbar and abdominal pain had persisted for more than 3 years and gradually aggravated in the last three months. There was no associated nausea or vomiting.

**History of past illness**
The illness history of the patient was unremarkable.

**Personal and family history**
The patient had no specific personal or family history of illnesses.

**Physical examination**
The vital parameters of the patient on the day of admission were as follows: body temperature, 36.3 °C; heart rate, 80 beats per min; respiratory rate, 18 breaths per min; blood pressure 125/80 mmHg; oxygen saturation in room air, 98%. There was mild tenderness in the left lumbar and abdominal area.

**Laboratory examinations**
Urinalysis, routine blood tests, coagulation indices, blood urea nitrogen, and liver function were normal. Urinary cytology revealed no heterocytes.

**Imaging examinations**
Abdominal contrast-enhanced computed tomography (CT) showed a right renal intrapelvic hypervascular space-occupying lesion sized 2.3 cm × 1.8 cm (Figure 1).

Histopathological findings identified the tumor as renal pelvis SFT (Figure 2). The size of the tumor was 2.7 cm×2.5 cm×1.6 cm. The mitotic image of the tumor was higher than 4/10 high power field (HPF). There were no signs of neurovascular invasion by tumor cells.

Immunohistochemical results were as follows: CD34(+), Desmin(-), H-caldesmon(-), SMA(+), STAT6(+), Vimentin(+), Bcl-2(+), CD117(-), Dog-1(-), HMB45(-), S-100(-), Ki-
67(+10%), CD99(+), and EMA(-). The immunohistochemical results confirmed the diagnosis of renal pelvis SFT.

**FINAL DIAGNOSIS**
The patient was diagnosed as left renal pelvis tumor.

**TREATMENT**
After weighing different treatment options, the patient underwent laparoscopic right nephroureterectomy.

**OUTCOME AND FOLLOW-UP**
The patient recovered well after the operation and was discharged after 5 days. The outcome was satisfactory, and there were no signs of recurrence during the three-years follow-up.

**DISCUSSION**
SFTs are rare mesenchymal tumors accounting for < 2% of all soft tissue tumors with an estimated annual incidence of 2 cases per million population\[^6\]. The age of reported cases of SFTs patients ranges between 4 and 85 years, and there is no clear predilection for any particular sex\[^3\]. SFTs mainly occur in the pleura. However, SFTs have also been reported at extrapulmonary sites, such as liver, mediastinum, breast, lung, meninges, and urogenital organs\[^7\]. According to previous reports, 15% of SFTs originating in kidneys are located in the renal capsule, 6% are located around the pelvis, 3% are located in the renal pelvis, and in 76% the site of origin was not clearly located\[^8\]. The first case of renal pelvis SFT was reported by Yazaki et al\[^9\] in 2001. Till date, only 15 cases of renal pelvis SFTs have been reported. As shown in Table 1, the renal pelvis SFT were listed.

Renal pelvis SFTs need to be differentiated from the more common renal pelvis tumors such as RCC, RAMLs, and UTUCs. Contrast-enhanced CT is the main method
for the diagnosis of RCCs\textsuperscript{[10]}. RCC is characterized by abundant blood supply, and tumor blood vessels and tumor staining can be observed on renal angiography. Contrast enhancement of renal pelvis SFTs is much lower than that of RCCs. UTUCs are another kind of common renal pelvis malignant tumor. Patients with UTUCs typically have a history of hematuria\textsuperscript{[11]}. In contrast, symptoms of renal pelvis SFTs are mostly due to pressure effect of the lesion, and these patients rarely develop urinary symptoms. The UTUCs show signs of infiltrative growth in CT images. Compared with UTUCs, renal pelvis SFT appears as a well-defined, heterogeneous or homogeneous mass showing moderate to marked contrast-enhancement. RAML is the most common renal benign tumor. Most RAMLs exhibit mixed density on CT imaging, due to the complex fatty vascular components.

In addition to RCCs, UTUCs, and RAMLs, there are also some rare tumor types including hemangiopericytomas, renal pelvis fibroepithelial polyps, fibromas, renal leiomyoma, and inflammatory myofibroblastic tumors\textsuperscript{[12]}. The imaging characteristics of renal pelvis SFTs are usually indistinguishable from those of these rare type tumors and the differential diagnosis is based on immunohistochemistry\textsuperscript{[13]}. According to the literature, some renal pelvis SFTs show areas of calcification, cystic change, or necrosis\textsuperscript{[14]}. These changes indicate aggressive nature of the tumor and poor prognosis.

In this case, the surgical method was laparoscopic right kidney and ureterectomy. There are currently no treatment guidelines for renal pelvis SFTs, but radical resection is generally chosen. Whether preoperative biopsy or nephron preservation surgery can improve the treatment efficacy and prognosis is not clear. For most cases of SFT, due to the malignant potential of SFTs and lack of recurrence after radical nephrectomy, a complete removal is recommended\textsuperscript{[15]}

Immunohistochemistry plays a key role in arriving at a definitive diagnosis. SFTs stain positive for Cluster Differentiation34 (CD34), Cluster Differentiation 99 (CD99), and B-cell lymphoma-2 (Bcl-2). Signal sensor and transcriptional activator 6 (STAT6) is also an antibody with high sensitivity for SFT diagnosis. These surface antigens are
useful diagnostic markers of SFT\textsuperscript{[3]}. It has been reported that CD-34 and Bcl-2 negative may indicate increased malignant potential\textsuperscript{[16]}. Although STAT6 is expressed in most SFTs, SFTs located in the renal pelvis have not been evaluated. Whether STAT6-negative status increases the malignant potential of renal pelvis SFTs is unknown. In this case, tumor tissue stained positive for CD34, vimentin, Bcl-2, STAT6, and CD99. It was considered as a benign renal SFT, and there was no local or distant metastasis after 3 years of follow-up. However, benign renal pelvis SFT may also have the ability for distant metastasis. Therefore, renal pelvis SFT is considered to be a "moderately malignant tumor that rarely metastasizes". Metastasis may occur in the lungs, liver, and bones\textsuperscript{[17]}. There are also reports of retroperitoneal recurrence\textsuperscript{[18]}. Rarely, the SFTs can also cause paraneoplastic syndromes such as Doege-Potter syndrome\textsuperscript{[19]}. Hence, all renal pelvis SFT patients need long-term follow-up and regular review, such as abdominal and lung CT.

**CONCLUSION**

We reported a rare case of renal pelvis SFT. Compared to the previously reported renal pelvis SFT tumors, the tumor in our patient was small in size and localized in the renal pelvis. Clinicians should pay attention to clarifying the source of kidney SFT and differentiate it from other renal pelvis cancers, so as to reduce the occurrence of misdiagnosis.
<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Words</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>nagasaki-u.repo.nii.ac.jp</td>
<td>22</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td><a href="http://www.wjgnet.com">www.wjgnet.com</a></td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>f6publishing.blob.core.windows.net</td>
<td>14</td>
<td>1</td>
</tr>
</tbody>
</table>